Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725047 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3ALDH1A1MAPT | |
| SCHEMBL31588379 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3ALDH1A1MAPT | |
| SCHEMBL29657386 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3ALDH1A1MAPT | |
| SCHEMBL30686153 | 0.89 | MDM2 (0.59) | MDM4TP53CASP3MDM2PTPN1 | |
| SCHEMBL29397862 | 0.89 | MDM2 (0.59) | MDM4TP53CASP3MDM2PTPN1 | |
| SCHEMBL29445591 | 0.89 | MDM2 (0.59) | MDM4TP53CASP3MDM2PTPN1 | |
| SCHEMBL2304915 | 0.89 | MDM2 (0.59) | MDM4TP53CASP3MDM2PTPN1 | |
| SCHEMBL3724885 | 0.89 | MDM2 (0.59) | MDM4TP53CASP3MDM2PTPN1 | |
| SCHEMBL2304920 | 0.89 | MDM2 (0.59) | MDM4TP53CASP3MDM2PTPN1 | |
| SCHEMBL12522498 | 0.89 | MDM4 (0.53) | MDM4TP53CASP3MDM2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112279888-B | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2022-09-13 | — | — | CN | claimed |
| CN-112279888-A | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2021-01-29 | — | — | CN | claimed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-112279888-B | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2022-09-13 | — | — | CN | disclosed |
| CN-112209991-B | Tripeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2022-08-12 | — | — | CN | disclosed |
| US-20220185846-A1 | METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDS | PROTAGONIST THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| CN-112279888-A | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2021-01-29 | — | — | CN | disclosed |
| WO-2020198682-A1 | METHODS FOR SYNTHESIZING β-HOMOAMINO ACIDS | PROTAGONIST THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-10407468-B2 | Methods for synthesizing α4β7 peptide antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20170327541-A1 | METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170327541-A1 | METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2017-11-16 | — | — | US | disclosed |
| WO-2017165676-A1 | METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407468-B2 | Methods for synthesizing α4β7 peptide antagonists | PSMA7, VIP, ITGB7 | MDM4 1713/4885TP53 3480/4885CASP3 3944/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885CASP3 3906/4885 |
| US-20220185846-A1 | METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDS | PSMA7, ITGB7, SCN7A | MDM4 2020/4885TP53 4405/4885CASP3 3125/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | MDM4 1060/4885TP53 573/4885CASP3 549/4885 |
| US-20170327541-A1 | METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS | PSMA7, PSMA4, IL4 | MDM4 363/4885TP53 3268/4885CASP3 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.